NOVARTIS (CAIN457F2206)

By June 19, 2019 Closed

A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at 12 weeks administered i.v. compared to s.c. in patients with active rheumatoid arthritis despite treatment with methotrexate

Leave a Reply